ERBB2 and ductal breast carcinoma in situ: Overall, both DCIS data and our findings in invasive disease emphasise the consistent prognostic significance of HER2 expression, highlighting the importance of incorporating HER2 status into risk stratification and post-neoadjuvant treatment decisions.